15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 10 firms covering Immunovant Inc, 6 rate it Buy or better, 4 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $18.00 to $62.00 (about 3.4x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $41.00 sits 2% above the current $40.11. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 5 to 6 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.53 next quarter toward $-2.05 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS10 ratings
Moderate Buy
Strong Buy00%
Buy660%
Hold440%
Sell00%
Strong Sell00%
Based on 10 analysts giving stock ratings to Immunovant Inc.
As of Jul, 6 of 9 firms rate IMVT a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
IMVT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.53
Range $-0.53 – $-0.53 · 1 analysts · -19% YoY
Next period, 1 analysts expect Immunovant Inc to earn $-0.53 a share (range $-0.53 – $-0.53), versus $-0.65 a year earlier. Full-year consensus is $-2.44, growing to $-2.05 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $39.7M next year.
Top analysts covering Immunovant Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IMVT.
#1
Yatin Suneja
Guggenheim · Rank #28
Buy
$62.00+54.6% to target
Overall win rate
52%
+ Follow
#2
Jason Gerberry
B of A Securities · Rank #136
Buy
$43.00+7.2% to target
Overall win rate
46%
+ Follow
#3
Yasmeen Rahimi
Piper Sandler · Rank #152
Buy
$66.00+64.5% to target
Overall win rate
34%
+ Follow
#4
Louise Chen
Cantor Fitzgerald · Rank #156
Buy
No targeton IMVT
Overall win rate
43%
+ Follow
#5
Douglas Tsao
HC Wainwright & Co. · Rank #212
Buy
$40.00-0.3% to target
Overall win rate
35%
+ Follow
IMVT stock forecast FAQ
What is IMVT's average 12-month price target?+
The 9 analysts with a live target average $41.00 for Immunovant Inc over the next 12 months, ranging from a $62.00 high to a $18.00 low.
Is IMVT stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 10 analyst ratings, 6 are Buy or Strong Buy, 4 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for IMVT?+
The Street-high target is $62.00 (Guggenheim), and the Street-low is $18.00 (UBS). The average of all 9 active targets is $41.00.
How many Wall Street analysts cover IMVT?+
10 analysts have an active rating on Immunovant Inc, and 9 firms carry a live 12-month price target.
Who is the most accurate analyst covering IMVT?+
Among analysts who currently cover IMVT, Yatin Suneja of Guggenheim has the strongest overall Quantellect track record (Rank #28). Their current call is Buy with a $62.00 target.
What is Immunovant Inc's projected EPS for next quarter?+
The consensus estimate is $-0.53 per share (range $-0.53 – $-0.53) across 1 analysts. Full-year EPS is projected at $-2.44, rising to $-2.05 the following year.
How much revenue is Immunovant Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $39.7M next year.
Have analysts been upgrading or downgrading IMVT lately?+
As of Jul, 6 of 9 firms rate IMVT a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IMVT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
